Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Acalabrutinib Induces Durable Disease Control in Frontline CLL at 4 Years

August 11th 2021

Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Thompson on the Evolving Role of MRD Testing in CLL

August 11th 2021

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLL

August 10th 2021

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Fixed-Duration Ibrutinib/Venetoclax Provides Deep, Durable Responses in Frontline CLL/SLL

August 10th 2021

A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).

BCL2 Inhibitors in Previously Untreated CLL

August 10th 2021

Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.

ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL

August 10th 2021

An overview of the h ALPINE trial of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Key Clinical Data for Frontline Targeted Therapy in CLL

August 9th 2021

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.

Global Approaches to the Frontline Management of CLL

August 9th 2021

Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.

Investigators Look to Enhance Response With Novel Triplet in CLL

August 5th 2021

Investigators of the phase 3 ULTRA-V trial are look-ing to leverage the synergistic capabilities of venetoclax for patients with chronic lymphocytic leukemia with the addition of the U2 regimen of ublituximab in combination with umbralisib.

Dr. Thompson on Future Research Directions in CLL

August 5th 2021

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

Mitigating Toxicities Associated With BTK Inhibitors

August 3rd 2021

A continuing discussion about the implications of toxicities with BTK inhibitors.

Safety and Efficacy of BTK Inhibitors in CLL

August 3rd 2021

A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).

Zanubrutinib Significantly Prolongs PFS Over Chemoimmunotherapy in Treatment-Naïve CLL

July 30th 2021

Zanubrutinib resulted in a significant improvement in progression-free survival per independent review committee assessment vs bendamustine plus rituximab in treatment-naïve patients with chronic lymphocytic leukemia whose tumors did not exhibit the deletion of chromosome 17p13.1.

Frontline Therapy for Patients With CLL: Testing and Risk Classification

July 30th 2021

A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.

Impact of Targeted Therapy in CLL

July 30th 2021

Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.

Dr. Roeker on the Emerging Role of MRD in CLL

July 27th 2021

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.

BTK Inhibitors as Frontline Treatment for CLL

July 27th 2021

Leukemia experts provide their personal experience using Bruton tyrosine kinase (BTK) inhibitors to treat patients with chronic lymphocytic leukemia (CLL) in the first-line setting.

Long-Term Experience With Ibrutinib in CLL

July 27th 2021

Jennifer Woyach, MD, discusses her experience using ibrutinib for chronic lymphocytic leukemia (CLL) in the first-line setting.

Dr. Thompson on Emerging Treatment Strategies With BTK Inhibitors in CLL

July 22nd 2021

Meghan Thompson, MD, discusses emerging treatment strategies with BTK inhibitors in chronic lymphocytic leukemia.

CLL: Prognostic Markers

July 20th 2021

An overview of prognostic models in chronic lymphocytic leukemia (CLL).